| Time (UTC+8) | Topic | Speaker | Moderator | Abstract | Slides | Video | |
|---|---|---|---|---|---|---|---|
| 08:20 - 08:30 | Opening Remarks |
Yen-Shen Lu
Fang-Ming Chen
|
|||||
| 08:30 - 09:00 | [Distinguished Pioneer Lecture] From Aromatase Biology to Single-Cell/Spatial Transcriptomics Analysis: A Lifetime Journey in Precision Oncology of Breast Cancer |
Shiuan Chen
|
King-Jen Chang
|
||||
| 09:00 - 09:30 | Session (1) From Evidence to Consensus: The Evolution and Global Impact of the NCCN Breast Cancer Guidelines: A Perspective from the Founding Chair of the NCCN Guidelines Panel for Breast Cancer |
William John Gradishar
|
Ming-Feng Hou
|
||||
| 09:30 - 10:00 | Session (1) From Global to Local: Ethnic and Geographic Impact in the Treatment of Breast Cancer Patient |
Shigehira Saji
|
Jyh-Cherng Yu
|
||||
| 10:00 - 10:40 | Session (1) Translating ctDNA Dynamics into Clinical Strategy: Innovation of Next-Generation SERD in 1L HR+/HER2- mBC |
François-Clément Bidard
|
Ling-Ming Tseng
|
||||
| 10:40 - 11:00 | Coffee Break | ||||||
| 11:00 - 11:40 | Session (1) The Sustainable Efficacy of CDK4/6 Inhibitor Therapy in HR+/HER2- Node+ High-Risk Early Breast Cancer |
Marc Thill
|
Ta-Chung Chao
|
||||
| 11:40 - 12:10 | Session (1) Impact and Pitfall of International Guideline and Real World Practice |
François-Clément Bidard
William John Gradishar
Shigehira Saji
Marc Thill
|
Fang-Ming Chen
|
||||
| 12:10 - 12:55 | [Luncheon Symposium (1)] Treatment Landscape for HR+/HER2- mBC with PI3K/AKT/PTEN Pathway Mutations |
Erica L. Mayer
|
Yen-Shen Lu
|
||||
| 12:55 - 13:10 | Coffee Break | ||||||
| 13:10 - 13:50 | Session (2) Redefining the Therapeutic Role of TKIs in HER2-Positive Metastatic Breast Cancer |
Virginia Borges
|
Fiona Tsui-Fen Cheng
|
||||
| 13:50 - 14:30 | Session (2) Redefining First-Line Treatment in HER2+ mBC: Insights from DESTINY-Breast09 |
Tom Wei-Wu Chen
|
Shin-Cheh Chen
|
||||
| 14:30 - 15:10 | Session (2) Defining the Optimal Sequence in HER2+ MBC: Balancing Category 1 Evidence with Emerging Frontline Data |
Chi-Feng Chung
|
Ming-Shen Dai
|
||||
| 15:10 - 15:30 | Coffee Break | ||||||
| 15:30 - 16:10 | Session (2) Longer Survival and Better Quality of Life: Two Endpoints to Be Considered in Metastatic HER2-Positive MBC |
Joohyuk Sohn
|
Ching-Hung Lin
|
||||
| 16:10 - 16:50 | Session (2) Improving Outcomes: Redefining High Risk and Care in HR+/HER2- Early Breast Cancer |
Dejan Juric
|
Hsien-Tang Yeh
|
||||
| 16:50 - 17:20 | Session (2) From Immune Infiltration to Immune Intervention: The Changing Landscape of Breast Cancer Immunotherapy |
Sherene Loi
|
Shyr-Ming Sheen-Chen
|
||||
| 17:20 - 18:00 | Session (2) Addressing Unmet Needs in TNBC: The Evolving Role of ADC Therapies |
Ching-Hung Lin
|
Tsu-Yi Chao
|
| Time (UTC+8) | Topic | Speaker | Moderator | Abstract | Slides | Video | |
|---|---|---|---|---|---|---|---|
| 09:30 - 09:50 | [TBCS-GBCC-JBCS-SSO] Joint Session: De-escalation of Breast Surgery: Who Can Safely Receive Less? |
Chin-Sheng Hung
|
Jun Won Min
Kuo-Ting Lee
|
||||
| 09:50 - 10:10 | [TBCS-GBCC-JBCS-SSO] Joint Session: Can Axillary Surgery Be Safely Omitted After Neoadjuvant Therapy? |
Laura S. Dominici
|
Jun Won Min
Kuo-Ting Lee
|
||||
| 10:10 - 10:30 | [TBCS-GBCC-JBCS-SSO] Joint Session: Breast Surgery in Young and High-Risk Patients: Where Is the Limit of De-escalation? |
Han-Byoel Lee
|
Jun Won Min
Kuo-Ting Lee
|
||||
| 10:30 - 10:50 | [TBCS-GBCC-JBCS-SSO] Joint Session: Is There Still a Role for Surgery in De Novo Stage IV Breast Cancer? |
Sung Gwe Ahn
|
Yutaka Yamamoto
Ming-Yang Wang
|
||||
| 10:50 - 11:10 | [TBCS-GBCC-JBCS-SSO] Joint Session: Precision Breast Surgery in Japan: Toward Surgical De-escalation After Systemic Therapy |
Hideo Shigematsu
|
Yutaka Yamamoto
Ming-Yang Wang
|
||||
| 11:10 - 11:30 | [TBCS-GBCC-JBCS-SSO] Joint Session: Setting the Future Standard of Breast Surgery: The SSO Perspective |
Mediget Teshome
|
Yutaka Yamamoto
Ming-Yang Wang
|
||||
| 11:30 - 12:00 | [TBCS-GBCC-JBCS-SSO] Joint Session: Discussion |
Sung Gwe Ahn
Laura S. Dominici
Han-Byoel Lee
Jun Won Min
Hideo Shigematsu
Mediget Teshome
Yutaka Yamamoto
Chin-Sheng Hung
Kuo-Ting Lee
Ming-Yang Wang
|
|||||
| 14:00 - 14:05 | [Young Doctors Forum] Opening |
Chi-Cheng Huang
|
|||||
| 14:05 - 14:30 | [Young Doctors Forum] From Trials to Practice: Interpreting Global Evidence in Modern Breast Cancer Care |
Marc Thill
|
|||||
| 14:30 - 14:55 | [Young Doctors Forum] TBD |
Laura S. Dominici
|
|||||
| 14:55 - 15:00 | [Young Doctors Forum] Q&A |
Laura S. Dominici
Marc Thill
|
|||||
| 15:00 - 15:05 | Break | ||||||
| 15:05 - 15:45 | [Young Doctors Debate] “No Scar, No Axilla?” Can Axillary Surgery Be Completely Omitted in Initially cN0 Triple-Negative or HER2-Positive Breast Cancer Patients Achieving Radiologic and Pathological Complete Response in the Breast After Neoadjuvant Systemic Therapy? |
Chia-Hui Chu
Chih-Hao Huang
Chieh-Ni Kao
I-Chen Tsai
Andrew Seto
Chayanee Sae-Lim
Nicola Raphaela Tison
Young-Won Lee
Nguyen Duc Toan
Basilie Teoh
Dahn Byun
Dewangga Ario
Hyung Suk Kim
Kwan Ho Lee
Kristalyn K. Gallagher
Mustafa Khanbhai
Yuri Fujimoto
Hsiang-Wei Huang
Pei-Hsuan Lee
|
Chiao Lo
|
||||
| 15:45 - 16:25 | [Young Doctors Debate] Pull the Trigger or Stay the Course? Should Endocrine Therapy Be Preemptively Switched Based Solely on Plasma ESR1 Mutation Detection via ctDNA Before Radiologic Progression in HR+/HER2- Advanced Breast Cancer? |
Shih-Yu Huang
Chia-Yen Hung
Wei-Nung Liu
Chan-Keng Yang
Arga Patrianagara
Mai Kitazawa
Jacqueline Tsai
Jun-Hee Lee
Asdi Wihandono
Chi Hoon Lee
Kibeom Kim
Desak Gede Agung Pramesti Devi
Sangjoon Park
Takako Kuroda
Saori Hayashi
Tomoe Taji
Jwo-Huey Yu
Wen-Ying Lin
Shang-Hsuan Peng
Meng-Xia Su
|
Tom Wei-Wu Chen
|
||||
| 16:25 - 16:30 | [Young Doctors Debate] Q&A Closing |
Jeong Eon Lee
|
|||||
| 16:30 - 16:50 | YDF/YDD Group Photo | ||||||
| 17:10 - 17:50 | The World's First NGS-Based Prognostic Assay and Real-World Clinical Experience in Korea |
Wonshik Han
|
Chiun-Sheng Huang
|
| Time (UTC+8) | Topic | Speaker | Moderator | Abstract | Slides | Video | |
|---|---|---|---|---|---|---|---|
| 10:30 - 16:00 | Oral Presentation | ||||||
| 16:30 - 17:05 | Beyond Physical Recovery: Body Image, Dyadic Interaction, and Intimacy in Breast Cancer Survivorship Care |
Su-Ying, Fang
|
Hsiu-Ling Chou
|
||||
| 17:05 - 17:40 | Beyond the Body: Reclaiming Who I Am -Psychological Healing and Readiness for Intimacy After Breast Cancer |
Szu-Ling Chiu
|
Kun-Ming Rau
|
||||
| 17:40 - 18:00 | Discussion |
Szu-Ling Chiu
Su-Ying, Fang
|
Kun-Ming Rau
Hsiu-Ling Chou
|
| Time (UTC+8) | Topic | Speaker | Moderator | Abstract | Slides | Video | |
|---|---|---|---|---|---|---|---|
| 11:10 - 11:50 | Let’s Meet the Master (1) Dejan Juric |
Dejan Juric
|
Hsu-Huan Chou
|
||||
| 12:20 - 13:00 | Let’s Meet the Master (2) Antonio Toesca |
Antonio Toesca
|
Wen-Ling Kuo
|
||||
| 13:30 - 14:10 | Let’s Meet the Master (3) William J Gradishar |
William John Gradishar
|
Chun-Yu Liu
|
||||
| 14:40 - 15:20 | Let’s Meet the Master (4) François-Clément Bidard |
François-Clément Bidard
|
I-Chun Chen
|
| Time (UTC+8) | Topic | Speaker | Moderator | Abstract | Slides | Video | |
|---|---|---|---|---|---|---|---|
| 08:10 - 08:50 | [Breakfast Symposium] Beyond the Fatigue Score: Immune Cell Profiling, Cytokine Signatures, and Inflammatory Correlates of PG2 in Breast Cancer |
Tom Wei-Wu Chen
Chun-Yu Liu
|
Kun-Ming Rau
|
||||
| 08:50 - 09:20 | Session (3) AI in BC Care: Translating AI into Precision Medicine |
Serene Goh
|
Chi-Cheng Huang
|
||||
| 09:20 - 09:50 | Session (3) Surgical De-escalation After Neoadjuvant Therapy: When Less Is More |
Susan Boolbol
|
Chen-Hsiang Chang
|
||||
| 09:50 - 10:10 | Coffee Break | ||||||
| 10:10 - 10:40 | Session (3) Cryoablation for Breast Cancer: 2026 Update |
Michael Berry
|
Yao-Jen Chang
|
||||
| 10:40 - 11:10 | Session (3) Robotic Nipple-Sparing Mastectomy: Technique, Outcomes, and Future Directions |
Antonio Toesca
|
Guo-Shiou Liao
|
||||
| 11:10 - 11:30 | Session (3) Discussion |
Susan Boolbol
Laura S. Dominici
Serene Goh
Antonio Toesca
|
|||||
| 11:30 - 12:10 | Session (4) Advancing the Management of ER+ HER2- mBC: Integrating Evidence and Experience |
Adam Matthew Brufsky
|
Liang-Chih Liu
|
||||
| 12:10 - 12:55 | [Luncheon Symposium (2)] One Step Further: Tackling the Unmet Needs to Reduce Recurrence Risk in HER2+ Breast Cancer |
Chin-Yao Lin
|
Dar-Ren Chen
|
||||
| 12:55 - 13:10 | Coffee Break | ||||||
| 13:10 - 13:50 | Session (5) Emerging ADC Treatment Strategies in Metastatic HR+/HER2− Breast Cancer |
Min Hwan Kim
|
Hsien-Kun Chang
|
||||
| 13:50 - 14:30 | Session (5) Evolving Treatment Landscape in HER2-Positive Early Breast Cancer (eBC): The Integration of ADC Therapies |
Sibylle Loibl
|
Chiun-Sheng Huang
|
||||
| 14:30 - 14:45 | Coffee Break | ||||||
| 14:45 - 15:25 | Session (5)Solo or Duet - Elevating Outcomes for Patients Starting 1L mTNBC Therapy by Anti-Trop2 ADC |
Dwan Ying Chang
|
Shou-Tung Chen
|
||||
| 15:25 - 15:45 | Session (5) Clinical experience with S-1 in Japan: evidence and practical integration in early breast cancer |
Masahiro Takada
|
Yuan-Ching Chang
|
||||
| 15:45 - 16:05 | Session (5) Practical Insights on Using TS-1 as Adjuvant Therapy in HR+/HER2− Early Breast Cancer: Cases, Tolerability, and Results |
Li-Kun Ko
|
Yuan-Ching Chang
|
||||
| 16:05 - 16:35 | Session (5) Disease Progression Under ADC, What Would We Do? Now and Future |
Naoto T. Ueno
|
Wen-Hung Kuo
|
||||
| 16:30 - 17:00 | Closing |
Yen-Shen Lu
Fang-Ming Chen
|
|||||
| 16:35 - 16:45 | Award Ceremony |
Yen-Shen Lu
Fang-Ming Chen
|
| Time (UTC+8) | Topic | Speaker | Moderator | Abstract | Slides | Video | |
|---|---|---|---|---|---|---|---|
| 09:30 - 10:10 | Evolving paradigms in HR+/HER2- eBC: The rise of next-generation oSERD |
Hsu-Huan Chou
|
Wen-Ling Kuo
|
||||
| 10:10 - 10:50 | Strategic Treatment Sequencing and Novel Approaches in 2L+ ER+/HER2–mBC |
Jason Aboudi Mouabbi
|
Jiun-I Lai
|
||||
| 10:50 - 11:30 | Real World Experience of Eribulin for Metastatic Breast Cancer |
Cheng-Wei Chou
|
Shih-Che Shen
|
||||
| 11:30 - 12:10 | Effectiveness of CDK4/6 inhibitor treatment for HR+/HER2- metastatic breast cancer |
Marc Thill
|
Chao-Ming Hung
|
||||
| 12:10 - 12:50 | [Luncheon Symposium (3)] From Access to Better Outcomes-The New Era of Early HER2-Positive Breast Cancer Care in Taiwan |
Chih-Hao Huang
|
Hsien-Tang Yeh
|
||||
| 12:50 - 13:00 | [Robotic Surgery Special Session] Global Approval Status of da Vinci Robotics in Breast Surgery |
Michael Berry
|
|||||
| 13:00 - 13:25 | [Robotic Surgery Special Session] Pioneering Robotic Mastectomy with Insightful Perspectives |
Antonio Toesca
|
Michael Berry
|
||||
| 13:25 - 13:50 | Learning Pathways and Training Models of Robotic Surgery |
Tristen Park
|
Han-Byoel Lee
|
||||
| 13:50 - 14:15 | Elements that Constitute Successful Robotic Breast Surgical Practice |
Wen-Ling Kuo
|
Ling-Ming Tseng
|
||||
| 14:15 - 14:40 | Reconstruction after Robotic Mastectomy |
Alice Yao
|
Fiona Tsui-Fen Cheng
|
||||
| 14:40 - 15:00 | Panel Discussion |
Michael Berry
Han-Byoel Lee
Tristen Park
Antonio Toesca
Alice Yao
Ling-Ming Tseng
Fiona Tsui-Fen Cheng
|
Wen-Ling Kuo
|